Taiwan-based vaccine maker Medigen will conduct a Phase 3 clinical trial for its COVID-19 vaccine in Europe once it has received approval from European authorities, which would help pave the way for its entry into European and other international markets, the company announced Wednesday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Cross-Strait
KMT caucus whip heads to Beijing to discuss cross-strait ties
04/26/2024 06:24 PM - Sports
Rakuten Monkeys' renovated stadium opener postponed due to rain
04/26/2024 05:57 PM - Business
Gaming console industry gives Taiwan huge business opportunities: Tsai
04/26/2024 05:48 PM - Business
Taiwan's 2024 GDP growth forecast raised to 3.29% due to AI boom
04/26/2024 04:55 PM - Politics
Visiting Ukrainian NGOs call for more support from Taiwan
04/26/2024 04:48 PM